PFE

Summary

Sell PFE Pfizer Inc. into strength 28.90-29.20. Extended +11-12% above 50/200 SMA at 28.59 resistance 29.02-29.33, momentum divergence. Liquidate trading lot, keep at most small income stub; no new longs. Risk above 29.33 (1.2x ATR), targets 28.00 then 27.50. Size small, ATR 0.60, avoid long premium at 47.4% IV. Horizon 5 trading days.

The case

1. Extended and crowded: our analysis sees shares 11%, 12% above long term moving averages with repeated rejections at the upper band, bearish momentum divergence and trading near the 98% high.

2. Uptrend intact but fragile: trend remains up above the short term average with prior overbought episodes resolving in brief consolidations, supported by oncology pipeline progress, settlement removing overhang, management change, defensive low beta profile and 5.93% yield.

3. Quality and valuation gap: Q2 free cash flow of $302M versus $2.45B dividend was uncovered, operating cash of $835M pressured by working capital drag and $3.467B tax paid and propped by $1.87B gain on sale plus $4.38B investment sales, alongside $63.2B debt, negative $33B tangible book, $4.3B recurring impairments, $1.1B exclusivity loss building toward decade end, undisclosed settlement amount, shrinking COVID market, heavily bullish social sentiment and 47.4% implied volatility into fear territory on a market fear gauge.

4. Action: sell into strength in stages, do not chase, reload only on a hold of lower support or a high volume band breakout with proof on oncology growth and dividend coverage.

What would weaken it

• Uptrend intact with gap risk above resistance
• Unknown liability and exclusivity loss overhang
• Crowded longs and elevated options premium